Welcome to our dedicated page for RSPID news (Ticker: RSPID), a resource for investors and traders seeking the latest updates and insights on RSPID stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RSPID's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RSPID's position in the market.
RespireRx Pharmaceuticals (OTCQB: RSPI) will participate in the Access China Biotech 2021 Digital conference from June 9-14, 2021. This event facilitates connections between Western pharmaceutical and biotech leaders and Chinese companies. RespireRx focuses on developing treatments for neurological disorders, specifically targeting conditions like obstructive sleep apnea and ADHD. The company aims to advance its innovative drug candidates based on cannabinoids and neuromodulators. Their corporate presentation is available online for stakeholders.
RespireRx Pharmaceuticals (OTCQB: RSPI) announces a significant advancement in spinal cord injury treatment. At the Annual Experimental Biology Conference, researchers presented findings demonstrating that low doses of AMPAkines CX717 and CX1739 effectively increase diaphragm activity and tidal volume in non-anesthetized rats post-cervical spinal cord injury. The ongoing collaboration with the University of Florida is focused on developing a Phase 2 clinical trial aimed at restoring motor functions in patients with spinal cord injury. This research highlights the potential of AMPAkines as a groundbreaking treatment option.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced significant advancements in its drug development programs targeting neurological disorders. The company is preparing to publish a review on its GABAkine compound, KRM-II-81, which shows promise in treating epilepsy, chronic pain, anxiety, and depression. Additionally, ongoing collaborations are expected to enhance AMPAkines for spinal cord injury recovery, and innovative formulations of dronabinol are in preclinical development for obstructive sleep apnea. While progress is noted, key compounds have yet to enter human trials, indicating risk in their future success.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has successfully up-listed from the OTC Pink Market to the OTCQB Venture Market, effective February 8, 2021. The company's ticker symbol has reverted to RSPI from RSPID. RespireRx focuses on developing innovative treatments for conditions such as obstructive sleep apnea and ADHD, leveraging its two main drug platforms: ResolutionRx (pharmaceutical cannabinoids) and EndeavourRx (neuromodulators). The management is considering separating these platforms into subsidiaries to optimize value and attract funding.
RespireRx Pharmaceuticals has been uplisted from the OTC Pink Market to the OTCQB Venture Market as of February 8, 2021. The ticker symbol has changed back to RSPI from RSPID. The company's focus is on developing treatments for various disorders including obstructive sleep apnea, ADHD, and chronic pain through two main drug platforms: ResolutionRx and EndeavourRx. RespireRx aims to enhance asset value by potentially establishing formal subsidiaries and engaging in strategic partnerships and business development efforts. However, there are no guarantees regarding successful transactions.